Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 12, Issue 6, 2002, Pages 704-709

  Aoki, Yoichi ^a   Sato, T ^a   Tsuneki, I ^a   Watanabe, M ^a   Kase, H ^a   Fujita, K ^a   Kurata, H ^a   Tanaka, K ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Carboplatin; Docetaxel; Neurotoxicity; Neutropenia; Ovarian cancer

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; INCIDENCE; JAPAN; LAPAROTOMY; LEUKOPENIA; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; UNIVERSITY HOSPITAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0036856316     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01118.x     Document Type: Article

References (22)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized inter-group trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000;92:699-708.
3. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 2000;18:106-15.
4. Ozols RF, Bundy BN, Fowler J et al. Phase III study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC). A Gynecologic Oncol Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:1373 (Abstract).
5. DuBois A, Lueck HJ, Meier W et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer. Update on an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 1999;18:1374 (Abstract).
6. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
7. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
8. Kaye SB. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol 1995;22:30-3.
9. Kaye SB, Piccart M, Aapro M, Kavanagh J. Docetaxel in advanced ovarian cancer, preliminary results from three phase II trials EORTC Early Clinical Trials Group and Clinical Screening Group and the MD Anderson Cancer Center. Eur J Cancer 1995;4(Suppl.):S14-7.
10. Piccart MJ, Gore M, Ten Bokkel Huinink W et al. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995;87;676-81.
11. Kavanagh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
12. Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000;18:2733-9.
13. Vasey PA, Paul J, Birt A et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer Scottish Gynaecological Cancer Trials Group. J Clin Oncol 1999;17:2069-80.
14. Vasey PA, Atkinson R, Coleman R et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84:170-8.
15. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001;19:1901-5.
16. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
17. 2 by 3-hour infusion. Br J Cancer 1998;77:1686-8.
18. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
19. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group CRC Clinical Trials Unit, Glasgow, UK, Glasgow, UK. Preliminary Results of the SCOTROC Trial. A phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) first-line chemotherapy for stage IC-IV epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2001;20:127 (Abstract).
20. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
21. Riva A, Fumoleau P, Roche H. Efficacy and safety of different corticosteroid (C) premedication (P) in breast cancer (BC) patients (pts) treated with Taxotere (T). Proc Am Soc Clin Oncol 1997;16:188a (Abstract).
22. Katsumata N, Tsunematsu R, Tanaka K et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese cooperative study. Ann Oncol 2000;11:1531-6.